How to Buy Bio Techne Stock
Bio Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide.
Bio Techne stock last closed at $47.51, down 1.23% from the previous day, and has decreased 24.35% in one year. It has overperformed other stocks in the Biotechnology industry by 0.53 percentage points. Bio Techne stock is currently +3.26% from its 52-week low of $46.01, and -44.48% from its 52-week high of $85.57.
There are currently 158.09M TECH shares outstanding. The market value of TECH is $7.51B. In the past 24 hours, 2.44M TECH shares were traded.
How to Buy Bio Techne Stock
Wondering how to invest in Bio Techne stock? Here's how.
- Decide where to buy Bio Techne stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you decide where to buy Bio Techne stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit money your brokerage account: Pick your method of payment and add your details.
- Evaluate Bio Techne stock: The Bio Techne ticker symbol is TECH. Is Bio Techne stock a good investment? Should you buy shares of TECH? How do TECH's underlying business fundamentals look? Do top analysts think Bio Techne is a good buy? Why has TECH's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if TECH is a good stock to buy).
- Execute your TECH buy order: Decide if you will purchase TECH shares at the current market price or use a limit order to buy TECH shares at a particular price.
- Get key alerts regarding your TECH investment: Create a watchlist to keep track of your position in Bio Techne stock.
Step 1: Decide where to buy Bio Techne stock
You need an online brokerage account to access the NASDAQ market and buy TECH stock.
Our preferred brokerage: eToro
Based on our research, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global financial markets: From Tech to Financial Services, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the right brokerage, it's time to fill out some personal information so you can buy TECH stock today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to open your new brokerage account.
- Send your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit money your brokerage account
Now that you've finished signing up on apps for stock market, your next step is to transfer the money for your investment:
Watch the tutorial below to see the process of depositing money into your investment account.
Step 4: Evaluate Bio Techne stock
Once you have chosen the best place to buy Bio Techne stock, it's critical to analyze their stock prior to investing, so you truly understand the risk as well as the opportunity.
Overview of key TECH info
TECH Fundamentals
WallStreetZen was created to help average investors do better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on TECH's stock page.
Is TECH stock undervalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge TECH's intrinsic value.
Using relative valuations metrics:
- TECH could be undervalued based on its P/E ratio of 47.51x, relative to Biotechnology industry P/E ratio of -184.27x
- TECH may be undervalued based on its P/B ratio of 3.61x, relative to Biotechnology industry P/B ratio of 4.04x
- TECH may be overvalued based on its PEG ratio of 1.33x
You can access additional valuation research on TECH's stock here.
A look at TECH Cashflows and Balance Sheet
Pros:
- Total TECH debt is lower than 5 years ago, relative to shareholder equity.
- TECH's operating cash flow of $304.72M allows it to safely service it's debt of $395.13M.
- TECH has a low debt to equity ratio of 0.29.
- There are more short-term assets than long-term liabilities on the TECH balance sheet.
- There are more short-term assets than short-term liabilities on the TECH balance sheet.
- TECH earnings of $201.53M is not enough to cover its interest payments.
Cons:
- TECH profit margin has gone down from 19.6% to 13.2% in the past year.
Do Wall Street analysts think it's a good time to buy TECH stock
Out of 6 Wall Street analysts who give forecasts on TECH, the consensus analyst rating on Bio Techne is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Most Recent TECH Analyst Ratings
John Vinh, a top 3% analyst from KeyBanc maintains TECH with a strong buy rating and raises their TECH price target from $80.00 to $90.00, on Feb 6, 2025.
KeyBanc's John Vinh raised their price target on Bio-Techne (NASDAQ: TECH) by 12.5% from $80 to $90 on 2025/02/06. The analyst maintained their Strong Buy rating on the stock.
Bio-Techne reported its Q2 2025 earnings.
In what KeyBanc sees as "a positive indicator for other life science tools companies," Bio-Techne's quarter was "a continuation of Q1's strength," Vinh said.
Earnings Report
For Q2 2025, Bio-Techne reported:
- EPS of $0.42, which beat the consensus estimate of $0.38 and Q2 2024's $0.40.
- Revenue of $297.03M, up from Q2 2024's $272.6M.
Management did not provide financial guidance in its press release.
President & CEO Kim Kelderman commented: "The Bio-Techne team once again executed at a high level and delivered strong Q2 results.
"It is encouraging to see early signs of improvement in the biopharma end-market, which was evident in our cell and gene therapy and protein analysis instrumentation businesses.
"We delivered this top-line result with a continued focus on profitability, which resulted in a 30.1% adjusted operating margin, an increase of 110 basis points sequentially."
"The Bio-Techne growth vectors empower the discovery of novel biological insights, the development and manufacturing of advanced therapeutics, and enable precision diagnostics.
"Our portfolio plays a key role in the healthy aging of global populations.
"Combining this unique portfolio with the talented Bio-Techne team positions the Company for continued differentiated financial performance."
You can dive deeper into what analysts are forecasting on the Bio Techne stock forecast page.
TECH Technicals
TECH Earnings
Last year, TECH earnings were $158.14M. Over the last five year, TECH's earnings have gone up by -4.82% per year. This was slower than the Biotechnology industry average of 10.61%.
Last year, TECH revenue was $1.20B. Over the past 5 year, TECH's revenue has gone up by 9.94% per year. This was slower than the Biotechnology industry average of 44.31%.
Learn more about TECH's earnings and revenue performance here.
Who is buying/selling TECH?
In the last 12 months, insiders at TECH have bought more shares than they have sold.
Shane Bohnen, SVP - General Counsel of TECH, was the latest TECH insider to sell. They sold $40,980.42 worth of TECH stock on Apr 3, 2025.
Learn more about who owns TECH stock here.
Does TECH stock generate passive income?
Bio Techne pays a dividend of 0.67%, compared to the Biotechnology industry's average dividend yield of 2.13%. If you owned $1,000 worth of TECH stock, you would have been paid $6.74 last year.
Bio Techne dividend payments have not consistently grown over the past decade and have not remained stable.
Dig into more info about Bio Techne dividend yield and history here.
What others are saying about TECH
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Execute your TECH buy order
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly fine for most investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at an exact price, place a limit order.
Press the Open Trade button and your broker will execute your order.
If you need more help buying stocks on eToro, click the helpful video below:
Step 6: Get key alerts regarding your TECH investment
Now that you own some TECH stock, you'll want to stay up-to-date on your new shares.
Create a watchlist to get alerted to the latest events about your TECH stock.
TECH Feed
How to Buy Stock in Bio Techne
To reiterate, here are the 6 steps you need to take to buy Bio Techne stock right now:
- Decide where to buy Bio Techne stock
- Open your brokerage account
- Deposit money your brokerage account
- Evaluate Bio Techne stock
- Execute your TECH buy order
- Get key alerts regarding your TECH investment
If you need a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get notifications regarding your investment in Bio Techne, hit the button below to create your watchlist.
Other "How To" Guides You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.